Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis

被引：15
|
作者：
Laskari, Katerina [1 ]
Tzioufas, Athanasios G. [1 ]
Antoniou, Anna [2 ]
Moutsopoulos, Haralampos M. [1 ]
机构：
[1] Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece
[2] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece
来源：
JOURNAL OF RHEUMATOLOGY | 2011年 / 38卷 / 07期
关键词：
LUPUS NEPHRITIS; MAINTENANCE TREATMENT; MYCOPHENOLATE MOFETIL; CLASSIFICATION; ERYTHEMATOSUS; THERAPY;
D O I：
10.3899/jrheum.101249
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Objective. To determine the timing for safe reduction of mycophenolate mofetil (MMF) dose during remission-maintenance therapy of proliferative lupus nephritis. Methods. The study population consisted of 44 patients evaluated retrospectively; MMF dose was empirically tapered in 18/44 patients until the latest observation. Results. Patients reducing MMF <= 18 months after remission/complete remission had a 6.8-fold/6.3-fold higher risk of relapse compared to those taking a stable dose (p = 0.001, p = 0.011, respectively). Reducing MMF later than 18 months was not associated with increased relapse rates. Conclusion. Reducing MMF > 1.5 years after remission/complete remission seems to warrant drug tapering without increased risk of disease flare in proliferative lupus nephritis. (J Rheumatol First Release April 15 2011; doi:10.3899/jrheum.101249)
引用
收藏
页码：1304 / 1308
页数：5
相关论文
共 50 条
  • [31] Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study
    Katerina Laskari
    Clio P Mavragani
    Athanasios G Tzioufas
    Haralampos M Moutsopoulos
    Arthritis Research & Therapy, 12
  • [32] Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis - Reply
    Chan, TM
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05): : 383 - 383
  • [33] Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring
    Zabotti, A.
    Baraldo, M.
    Quartuccio, L.
    Sacco, S.
    De Marchi, G.
    De Vita, S.
    CLINICAL RHEUMATOLOGY, 2015, 34 (01) : 171 - 174
  • [34] Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring
    A. Zabotti
    M. Baraldo
    L. Quartuccio
    S. Sacco
    G. De Marchi
    S. De Vita
    Clinical Rheumatology, 2015, 34 : 171 - 174
  • [35] Mycophenolate mofetil in the treatment of lupus nephritis - 7 years on
    Chan, Tak Mao
    LUPUS, 2008, 17 (07) : 617 - 621
  • [36] What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?
    Jones, Rachel B.
    Walsh, Michael
    Smith, Kenneth G. C.
    CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (03) : 256 - 261
  • [37] Mycophenolate mofetil seems to be superior to Azothioprine in Maintenance therapy of Lupus nephritis
    Schmalzing, M.
    Koetter, I.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2012, 71 (09): : 813 - 815
  • [38] Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study
    Ding, L
    Zhao, MH
    Zou, WZ
    Liu, YC
    Wang, HY
    LUPUS, 2004, 13 (02) : 113 - 118
  • [39] Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis
    Hu, WX
    Liu, ZH
    Chen, HP
    Tang, Z
    Wang, QW
    Shen, KQ
    Li, LS
    CHINESE MEDICAL JOURNAL, 2002, 115 (05) : 705 - 709
  • [40] Mycophenolate mofetil for lupus nephritis: an update
    Mok, Chi Chiu
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (12) : 1353 - 1364
12345